Lido Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.4M | Buy |
153,825
+33,233
| +28% | +$4.38M | 0.05% | 234 |
|
|
2026
Q1 | $16.8M | Sell |
120,592
-2,772
| -2% | -$388K | 0.05% | 229 |
|
|
2025
Q4 | $14.5M | Buy |
123,364
+2,143
| +2% | +$260K | 0.04% | 255 |
|
|
2025
Q3 | $13.5M | Buy |
121,221
+54,411
| +81% | +$6.18M | 0.04% | 260 |
|
|
2025
Q2 | $7.41M | Sell |
66,810
-2,836
| -4% | -$302K | 0.03% | 296 |
|
|
2025
Q1 | $7.8M | Buy |
69,646
+5,892
| +9% | +$608K | 0.04% | 268 |
|
|
2024
Q4 | $5.89M | Buy |
63,754
+4,680
| +8% | +$421K | 0.03% | 297 |
|
|
2024
Q3 | $4.95M | Buy |
59,074
+944
| +2% | +$72K | 0.02% | 309 |
|
|
2024
Q2 | $3.99M | Sell |
58,130
-1,685
| -3% | -$112K | 0.02% | 319 |
|
|
2024
Q1 | $4.38M | Buy |
59,815
+7,307
| +14% | +$562K | 0.03% | 302 |
|
|
2023
Q4 | $4.25M | Buy |
52,508
+823
| +2% | +$64K | 0.03% | 289 |
|
|
2023
Q3 | $3.87M | Buy |
51,685
+6,985
| +16% | +$537K | 0.03% | 281 |
|
|
2023
Q2 | $3.45M | Sell |
44,700
-35,205
| -44% | -$2.81M | 0.02% | 273 |
|
|
2023
Q1 | $6.63M | Sell |
79,905
-2,444
| -3% | -$202K | 0.06% | 171 |
|
|
2022
Q4 | $7.07M | Buy |
82,349
+53,331
| +184% | +$4.22M | 0.09% | 126 |
|
|
2022
Q3 | $1.79M | Buy |
29,018
+20,073
| +224% | +$1.27M | 0.02% | 278 |
|
|
2022
Q2 | $552K | Sell |
8,945
-2,084
| -19% | -$129K | 0.01% | 512 |
|
|
2022
Q1 | $655K | Buy |
11,029
+100
| +0.9% | +$6.39K | 0.01% | 514 |
|
|
2021
Q4 | $793K | Sell |
10,929
-59
| -0.5% | -$4.06K | 0.01% | 473 |
|
|
2021
Q3 | $767K | Sell |
10,988
-33,949
| -76% | -$2.39M | 0.01% | 466 |
|
|
2021
Q2 | $3.09M | Sell |
44,937
-1,231
| -3% | -$82.2K | 0.04% | 205 |
|
|
2021
Q1 | $2.98M | Buy |
46,168
+15,994
| +53% | +$1.03M | 0.05% | 181 |
|
|
2020
Q4 | $1.76M | Sell |
30,174
-53,366
| -64% | -$3.22M | 0.04% | 226 |
|
|
2020
Q3 | $5.28M | Buy |
83,540
+10,199
| +14% | +$707K | 0.14% | 91 |
|
|
2020
Q2 | $5.64M | Buy |
73,341
+48,363
| +194% | +$3.71M | 0.17% | 77 |
|
|
2020
Q1 | $1.87M | Sell |
24,978
-4,348
| -15% | -$300K | 0.08% | 136 |
|
|
2019
Q4 | $1.91M | Buy |
29,326
+24,313
| +485% | +$1.58M | 0.08% | 151 |
|
|
2019
Q3 | $318K | Sell |
5,013
-3,623
| -42% | -$237K | 0.02% | 430 |
|
|
2019
Q2 | $583K | Sell |
8,636
-438
| -5% | -$28.8K | 0.03% | 274 |
|
|
2019
Q1 | $589K | Buy |
9,074
+7
| +0.1% | +$465 | 0.04% | 259 |
|
|
2018
Q4 | $567K | Buy |
9,067
+3,149
| +53% | +$220K | 0.06% | 203 |
|
|
2018
Q3 | $456K | Buy |
5,918
+552
| +10% | +$41.7K | 0.04% | 258 |
|
|
2018
Q2 | $380K | Sell |
5,366
-26
| -0.5% | -$1.84K | 0.04% | 261 |
|
|
2018
Q1 | $406K | Sell |
5,392
-839
| -13% | -$66.7K | 0.06% | 224 |
|
|
2017
Q4 | $446K | Sell |
6,231
-652
| -9% | -$49.5K | 0.06% | 170 |
|
|
2017
Q3 | $515K | Buy |
6,883
+3,261
| +90% | +$249K | 0.08% | 143 |
|
|
2017
Q2 | $256K | Buy |
+3,622
| New | +$241K | 0.05% | 211 |
|
|
2016
Q3 | – | Sell |
-2,712
| Closed | -$226K | – | 169 |
|
|
2016
Q2 | $226K | Sell |
2,712
-2,821
| -51% | -$250K | 0.07% | 135 |
|
|
2016
Q1 | $508K | Buy |
+5,533
| New | +$499K | 0.17% | 57 |
|
Other funds holding GILD
Lido Advisors's GILD Position: Q2 2026 in Review
Lido Advisors increased its Gilead Sciences (GILD) stake by 28% in Q2 2026, buying an estimated $4.38M and bringing the position to 153,825 shares worth $19.4M. The position accounts for 0.05% of the portfolio, ranked #234.
Lido Advisors first reported a position in GILD in Q1 2016 and has held it in 39 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Lido Advisors held 153,825 shares of Gilead Sciences worth $19.4M as of Q2 2026.
- Lido Advisors bought 33,233 Gilead Sciences shares in Q2 2026, an estimated $4.38M.
- Gilead Sciences made up 0.05% of Lido Advisors's portfolio in Q2 2026, its #234 holding.
- Lido Advisors first reported a position in Gilead Sciences in Q1 2016 and has held it in 39 quarters since.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.